

5-Chlorocarbonyl-10,11-dihydro-5H-dibenz[*b,f*]azepineT. Vijay,^a H. G. Anilkumar,^b
H. S. Yathirajan,^b
T. Narasimhamurthy^c and
R. S. Rathore^{d*}^aSolid State and Structural Chemistry Unit,
Indian Institute of Science, Bangalore 560 012,
India, ^bDepartment of Studies in Chemistry,
University of Mysore, Manasagangotri, Mysore
570 006, India, ^cCCD Facility, Indian Institute of
Science, Bangalore 560 012, India, and
^dOriental Organization of Molecular and
Structural Biology, 204 Agarwal Bhavan,
Malleshwaram, Bangalore 560 055, IndiaCorrespondence e-mail:
ravindranath_rathore@yahoo.com


Key indicators

Single-crystal X-ray study
T = 295 K
Mean $\sigma(\text{C}—\text{C})$ = 0.005 Å
R factor = 0.063
wR factor = 0.119
Data-to-parameter ratio = 17.7For details of how these key indicators were
automatically derived from the article, see
<http://journals.iucr.org/e>.

In the title compound, C₁₅H₁₂ClNO, the central seven-membered azepine ring adopts a bent conformation, intermediate between the boat and chair forms. The overall structure of the molecule is similar to a butterfly shape, which is commonly observed for carbamazepine analogues. The planes through the benzene rings on either side of the azepine ring intersect at an angle of 59.0 (1)°. The molecular assembly is primarily stabilized by aromatic π – π interactions.

Comment

Carbamazepine and its analogues, which belong to the family of iminostilbenes, have been widely used therapeutically as anticonvulsant agents (Pearce *et al.*, 2002; Czapinski *et al.*, 2005). In order to study the structure–activity relationships of these compounds, numerous structures of iminostilbene derivatives have been reported (Lisgarten *et al.*, 1989; Lang *et al.*, 2002; Hempel *et al.*, 2005; Nagaraj *et al.*, 2005; Johnston *et al.*, 2005). The crystal structure analysis of the title compound, (I), reported here was undertaken as a part of an ongoing programme of structural studies of molecules of pharmaceutical interest.



The molecular structure and conformation of (I) are shown in Fig. 1. The planes of atoms N5/C1–C4/C11–C13 and N5/C6–C9/C10/C11/C14/C15 intersect at an angle of 59.0 (1)°. The central seven-membered azepine ring (N5/C10–C15) adopts a bent conformation with five coplanar atoms (N5/C10/C11/C14/C15) (Bocian *et al.*, 1975; Bocian & Strauss, 1977). Six distinct conformations have been identified and characterized for a classical cycloheptane ring: (i) boat, (ii) chair, (iii) twist-boat, (iv) twist-chair, and the two high-energy intermediate transition states, namely, (v) bent transition state between the first two and, (vi) twisted transition state between the latter two (Hendrickson, 1961, 1967; Bocian *et al.*, 1975; Bocian & Strauss, 1977). The bent transition state of the seven-membered ring with five coplanar atoms is one of the most popular conformation among carbamazepine analogues, which has been improperly referred as twist-boat or half-boat by many authors. In addition to the puckering parameters of the ring described in the literature (Bocian *et al.*, 1975; Bocian & Strauss, 1977), the ‘twist’ nomenclature in its classical sense

Received 19 September 2005
Accepted 26 September 2005
Online 19 October 2005

mean the form with C_2 (axial) symmetry (Hendrickson, 1961, 1967), while the present conformation of the ring possesses C_s (mirror plane) symmetry. The puckering parameters (Cremer & Pople, 1975) of the azepine ring are, $q_2 = 0.813$ (3) Å, $q_3 = 0.284$ (3) Å, $\varphi_2 = 202.9$ (2)° and $\varphi_3 = 125.4$ (7)°, and the total puckering amplitude $Q_T = 0.861$ (3) Å. The internal torsion angles of the azepine ring are indicated in Fig. 1. The bent conformation of the seven-membered ring possesses a mirror symmetry about the plane passing through atom C15 and bisecting the C12—C13 bond. The asymmetry parameter (Duax *et al.*, 1976), $\Delta C_s(m)$, is 8.2°. Due to the present conformation of the azepine ring, the molecule assumes a butterfly shape, as previously observed (Hempel *et al.*, 2005; Nagaraj *et al.*, 2005).

In the absence of any potential hydrogen-bond donors, the crystal packing of (I) is mainly stabilized by aromatic π – π interactions of the edge-to-face type, in addition to van der Waals forces (Fig. 2). The geometric parameters, *i.e.* centroid...centroid separations, interplanar angles and minimal C—C separations in the π – π interactions, respectively, are as follows $Cg1 \cdots Cg1(2 - x, 2 - y, -\frac{1}{2} + z) = 4.926$ (2) Å, 32.3°, 3.46 Å; $Cg1 \cdots Cg2(2 - x, 1 - y, \frac{1}{2} + z) = 5.057$ (2) Å, 79.0°, 3.60 Å; $Cg2 \cdots Cg2(\frac{3}{2} - x, y, -\frac{1}{2} + z) = 4.987$ (2) Å, 70.5°, 3.76 Å. $Cg1$ and $Cg2$ are the centroids of ring 1 (atoms C1–C4/C12/C13) and ring 2 (atoms C6–C9/C14/C15), respectively.

Experimental

The title compound (Jubilant Organosys, Nanjangaud, India) was crystallized from ethyl methyl ketone.

Crystal data


$C_{15}H_{12}ClNO$	Mo $K\alpha$ radiation
$M_r = 257.71$	Cell parameters from 870 reflections
Orthorhombic, $Pca2_1$	$\theta = 5\text{--}27^\circ$
$a = 16.654$ (3) Å	$\mu = 0.28$ mm $^{-1}$
$b = 10.646$ (2) Å	$T = 295$ (2) K
$c = 7.2599$ (14) Å	Plate, colourless
$V = 1287.1$ (4) Å 3	$0.58 \times 0.20 \times 0.12$ mm
$Z = 4$	
$D_x = 1.330$ Mg m $^{-3}$	

Data collection

Bruker SMART CCD area-detector diffractometer	2890 independent reflections
φ and ω scans	2159 reflections with $I > 2\sigma(I)$
Absorption correction: multi-scan (SADABS; Sheldrick, 1996)	$R_{int} = 0.032$
$T_{min} = 0.926$, $T_{max} = 0.971$	$\theta_{max} = 27.9^\circ$
6801 measured reflections	$h = -18 \rightarrow 21$
	$k = -14 \rightarrow 11$
	$l = -9 \rightarrow 8$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0482P)^2 + 0.0447P]$
$R[F^2 > 2\sigma(F^2)] = 0.063$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.119$	$(\Delta/\sigma)_{max} < 0.001$
$S = 1.13$	$\Delta\rho_{max} = 0.29$ e Å $^{-3}$
2890 reflections	$\Delta\rho_{min} = -0.18$ e Å $^{-3}$
163 parameters	Absolute structure: Flack (1983), with 1414 Friedel pairs
H-atom parameters constrained	Flack parameter: 0.03 (10)



References

- Bocian, D. F., Pickett, H. M., Rounds, T. C. & Strauss, H. L. (1975). *J. Am. Chem. Soc.* **97**, 687–695.
- Bocian, D. F. & Strauss, H. L. (1977). *J. Am. Chem. Soc.* **99**, 2876–2882.
- Bruker (2000). *SHELXTL*. Version 6.10. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2001). *SMART* (Version 5.628) and *SAINT-Plus* (Version 6.02a). Bruker AXS Inc., Madison, Wisconsin, USA.
- Cremer, D. & Pople, J. A. (1975). *J. Am. Chem. Soc.* **97**, 1354–1358.
- Czapinski, P., Blaszczyk, B. & Czuczwar, S. J. (2005). *Curr. Top. Med. Chem.* **5**, 3–14.
- Duax, W. L., Weeks, C. M. & Rohrer, D. C. (1976). *Topics in Stereochemistry*, Vol. 9, edited by E. L. Eliel & N. Allinger, pp. 271–383. New York: John Wiley.
- Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
- Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.
- Hempel, A., Camerman, N., Camerman, A. & Mastropalo, D. (2005). *Acta Cryst.* **E61**, o1313–1315.
- Hendrickson, J. B. (1961). *J. Am. Chem. Soc.* **83**, 4537–4547.
- Hendrickson, J. B. (1967). *J. Am. Chem. Soc.* **89**, 7047–7061.
- Johnston, A., Florence, A. J. & Kennedy, A. R. (2005). *Acta Cryst.* **E61**, o1777–1779.
- Lang, M., Kampf, J. W. & Matzger, A. J. (2002). *J. Pharm. Sci.* **91**, 1186–1190.
- Lisgarten, J. N., Palmer, R. A. & Saldanha, J. W. (1989). *Acta Cryst.* **C45**, 656–658.
- Nagaraj, B., Yathirajan, H. S. & Lynch, D. (2005). *Acta Cryst.* **E61**, o1609–1610.
- Pearce, R. E., Vakkalagadda, G. R. & Steven Leeder, J. (2002). *Drug Metab. Dispos.* **30**, 1170–1179.
- Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.